CIBC Bancorp USA’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$576K Buy
10,408
+3,486
+50% +$188K ﹤0.01% 1290
2026
Q2
$378K Buy
6,922
+37
+0.5% +$1.95K ﹤0.01% 1418
2026
Q1
$328K Buy
+6,885
New +$363K ﹤0.01% 1375
2025
Q3
$572K Buy
+8,824
New +$507K ﹤0.01% 812

Other funds holding CRSP

CIBC Bancorp USA's CRSP Position: Q3 2026 in Review

CIBC Bancorp USA increased its CRISPR Therapeutics (CRSP) stake by 50% in Q3 2026, buying an estimated $188K and bringing the position to 10,408 shares worth $576K. The position accounts for ﹤0.01% of the portfolio, ranked #1290.

CIBC Bancorp USA first reported a position in CRSP in Q3 2025 and has held it in 4 quarters since. 504 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • CIBC Bancorp USA held 10,408 shares of CRISPR Therapeutics worth $576K as of Q3 2026.
  • CIBC Bancorp USA bought 3,486 CRISPR Therapeutics shares in Q3 2026, an estimated $188K.
  • CRISPR Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1290 holding.
  • CIBC Bancorp USA first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 504 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.